ReviewDrugs & aging2019
Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.
Review in Drugs & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Guideline
- Imaging methods in polymyalgia rheumatica: a systematic review.Rheumatology international · 2023Pooled it
- Monocytes/Macrophages in Giant Cell Arteritis-Polymyalgia Rheumatica Spectrum Disease.Aging and disease · 2025Review
- Ultrasound-detected bilateral subacromial-subdeltoid bursitis exceeding 3 mm differentiates polymyalgia rheumatica from rotator cuff tendinopathy: a cross-sectional observational study.Rheumatology international · 2025Observational
- Soluble Co-Inhibitory Immune Checkpoint Molecules Are Increased in Patients With Polymyalgia Rheumatica Without Significant Correlations With Clinical Status: A Case-Control Study.ACR open rheumatology · 2025Article
- Current Trends in Clinical Trials of Prodrugs.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement.Rheumatology (Oxford, England) · 2025Article
- Predictors of giant cell arteritis in patients with polymyalgia rheumatica in southern Sweden-a retrospective study.Rheumatology advances in practice · 2025Article
- Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.Journal of clinical medicine · 2024Review
- Why is polymyalgia rheumatica a disease of older adults? Explanations through etiology and pathogenesis: a narrative review.Clinical rheumatology · 2024Review
- [Polymyalgia rheumatica-A challenge in geriatrics : Interdisciplinary presentation of diagnostics and treatment].Zeitschrift fur Rheumatologie · 2024Article
- Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature.Reumatologia · 2024Review
- Water vapor therapy and polymyalgia rheumatica: Coincidental?Journal of family medicine and primary care · 2023Article
- [Polymyalgia rheumatica-A challenge in geriatrics : Interdisciplinary presentation of diagnostics and treatment].Zeitschrift fur Gerontologie und Geriatrie · 2023Article
- Article
- Effects of Whole-Body Cryostimulation on Pain Management and Disease Activity in Active Rheumatic Polymyalgia: A Case-Report.Biomedicines · 2023Article
- Article
- In Reply.Deutsches Arzteblatt international · 2023Article
- Article
- Efficacy of JAK Inhibitors versus DMARDs in the Treatment of Polymyalgia Rheumatica in China.International journal of general medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polymyalgia rheumatica is an inflammatory rheumatic disease of the elderly characterised by pain and stiffness in the neck and pelvic girdle, and is the second most common inflammatory rheumatic condition in this age group, after rheumatoid arthritis. Polymyalgia rheumatica can occur independently or in association with giant cell arteritis, which is the most common form of primary vasculitis. The diagnosis of polymyalgia rheumatica is usually based on clinical presentation and increase of inflammatory markers. There are no pathognomonic findings that can confirm the diagnosis. However, different imaging techniques, especially ultrasonography, can assist in the identification of polymyalgia rheumatica. Glucocorticoids are the cornerstone of the treatment of polymyalgia rheumatica, but they might be associated with different adverse events. A subgroup of patients presents with a refractory disease course and, in these cases, adding methotrexate as a steroid-sparing agent could be useful. In this review, we summarise the latest findings regarding the pathogenesis, diagnosis and management of polymyalgia rheumatica and try to highlight the possible pitfalls, especially in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.